Company news

EchoIQ Limited news in 2025

EchoIQ Limited's news releases, calls and decks from 2025, newest first.

View company

Formal lodgement of FDA submission for EchoSolv HF

December 14, 2025

Echo IQ to Present at the Life Sciences Virtual Investor Forum on 11th December

December 8, 2025

Validation study for EchoSolv HF completed at the Mayo Clinic – Study delivers exceptional results

November 24, 2025

Exceptional Results from Validation Study for EchoSolv HF

November 23, 2025

Echo IQ to Participate in the Piper Sandler 37th Annual Healthcare Conference

November 21, 2025

Echo IQ Highlights Market Potential for EchoSolv AS Following Presentation of New Data for Severe Aortic Stenosis (AS) Presented at AHA Scientific Sessions 2025

November 12, 2025

Quarterly Activities and Appendix 4C Cash Flow Report

October 30, 2025

Category III CPT code application update

October 6, 2025

Trading Halt

October 5, 2025

Pause in Trading

October 5, 2025

Strong Operational Momentum

October 2, 2025

Update on Category III CPT Code Application

September 19, 2025

Preliminary Final Report

August 29, 2025

Quarterly Activities & Appendix 4C Cashflow Reports

July 24, 2025

Reseller Agreement Secured with SARC MedIQ

July 10, 2025

Mayo Clinic Validation Study Underway

July 1, 2025

Echo IQ raises $17.3m via institutional placement

May 7, 2025

Listing on the OTCQB Market

April 16, 2025

Echosolv Collaboration Agreement with Mayo Clinic Platform

April 2, 2025

Echo IQ signs strategic partnership and integration agreements with ScImage and MedAxiom to expand EchoSolv AS across 36 US cardiology networks

April 1, 2025

Expansion Across 36 US Hospitals and Cardiology Practices

March 30, 2025

Investor Webinar Presentation

March 6, 2025

Strong Progress in First Two Months of CY25 Achieved

March 4, 2025

Appendix 4D 31 December 2024

February 27, 2025

$1.26M R&D tax incentive received

February 12, 2025

Response to ASX Query Letter

January 31, 2025

Decks in 2025